StemCell Therapy

Durham, NC (PRWEB) February 03, 2014

Previous studies have shown that multiple stem cell implantations might assist adults suffering from complete spinal cord injuries (SCI). Now a groundbreaking study released today in STEM CELLS Translational Medicine shows for the first time that children with SCI might benefit, too.

Marcin Majka, Ph.D., and Danuta Jarocha, Ph.D., led the study at Jagiellonian University College of Medicine in Krakow, Poland. "Although it was conducted on a small number of patients carrying a different injury level and type, preliminary results demonstrate the possibility of attaining neurological, motor and sensation and quality-of-life improvement in children with a chronic complete spinal cord injury through multiple bone marrow derived cell (BMNC) implantations. Intravenous implantations of these cells seem to prevent and/or help the healing of pressure ulcers," Dr. Majka said.

The study involved five children, ranging in age from 3 to 7, all of whom were patients at University Childrens Hospital in Krakow. Each had suffered a spinal cord injury at least six months prior to the start of the stem cell program and was showing no signs of improvement from standard treatments. The patients collectively underwent 19 implantation procedures with BM-derived cells, with every treatment cycle followed by an intensive four weeks of rehabilitation.

The children were evaluated over a one to six year period for sensation and motor improvement, muscle stiffness and bladder function. Any improvement in their quality of life was also noted, based on estimated functional recovery. Additionally, the development of neuropathic pain, secondary infections, urinary tract infections or pressure ulcers was tracked.

"Two of the five children receiving the highest number of transplantations demonstrated neurological and quality-of-life improvements," Dr. Jarocha said. "They included a girl who, before the stem cell implantations, had to be tube fed and needed a ventilator to breathe. She is now able to eat and breathe on her own."

The study also demonstrated no long-term side effects from the BMNCs, leading the researchers to conclude that single and multiple BMNCs implantations were safe for pediatric patients as well as adults.

Interestingly, when the scientists compared their study with those done on adults, the results did not suggest an advantage of the younger age. "This is somehow unexpected since the younger age should provide better ability to regenerate. Since the present study was done on a small number of patients, a larger study using the same methodology for pediatric and adult patients allowing a direct comparison should be performed to confirm or contradict the observation. Larger studies with patients segregated according to the type and level of the injury with the same infusion intervals should be performed to obtain more consistent data, too," Dr. Majka added.

"While this studys sample is small, it is the first to report the safety and feasibility of using bone marrow derived cells to treat pediatric patients with complete spinal cord injury," said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "The treatment resulted in a degree of neurological and quality-of-life improvement in the study participants."

The full article, "Preliminary study of autologous bone marrow nucleated cells transplantation in children with spinal cord injury," can be accessed at http://www.stemcellstm.com.

Original post:
First Study Tracking Stem Cell Treatments For Children With Spinal Cord Injuries Shows Potential Benefit

PUBLIC RELEASE DATE:

30-Jan-2014

Contact: Bill Hathaway william.hathaway@yale.edu 203-432-1322 Yale University

A fundamental axiom of biology used to be that cell fate is a one-way street once a cell commits to becoming muscle, skin, or blood it always remains muscle, skin, or blood cell. That belief was upended in the past decade when a Japanese scientist introduced four simple factors into skin cells and returned them to an embryonic-like state, capable of becoming almost any cell type in the body.

Hopeful of revolutionary medical therapies using a patient's own cells, scientists rushed to capitalize on the discovery by 2012 Nobel Laureate Shinya Yamanaka. However, the process has remained slow and inefficient, and scientists have had a difficult time discovering a genetic explanation of why this should be.

In the Jan. 30 issue of the journal Cell, Yale School of Medicine researchers identified a major obstacle to converting cells back to their youthful state the speed of the cell cycle, or the time required for a cell to divide.

When the cell cycle accelerates to a certain speed, the barriers that keep a cell's fate on one path diminish. In such a state, cells are easily persuaded to change their identity and become pluripotent, or capable of becoming multiple cell types

"One analogy may be that when temperature increases to sufficient degrees, even a very hard piece of steel can be malleable so that you can give it a new shape easily," said Shangqin Guo, assistant professor of cell biology at the Yale Stem Cell Center and lead author of the paper. "Once cells are cycling extremely fast, they do not seem to face the same barriers to becoming pluripotent."

Guo's team studied blood-forming cells, which when dividing undergo specific changes in their cell cycle to produce new blood cells. Blood-forming progenitor cells normally produce only new blood cells. However, the introduction of Yamanaka factors sometimes but not always help these blood-forming cells become other types of cells. The new report finds that after this treatment blood-forming cells tend to become pluripotent when the cell cycle is completed in eight hours or less, an unusual speed for adult cells. Cells that cycle more slowly remain blood cells.

"This discovery changes the way people think about how to change cell fate and reveals that a basic 'house-keeping' function of a cell, such as its cell cycle length, can actually have a major impact on switching the fate of a cell," said Haifan Lin, director of the Yale Stem Cell Center.

See original here:
Cell cycle speed is key to making aging cells young again

PUBLIC RELEASE DATE:

29-Jan-2014

Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles

Scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research were today awarded grants totaling more than $3.5 million by California's stem cell agency for their ongoing efforts to advance revolutionary stem cell science in medicine.

Recipients of the awards from the California Institute of Renerative Medicine (CIRM) included Lili Yang ($614,400), who researches how stem cells become rare immune cells; Denis Evseenko ($1,146,468), who is studying the biological niche in which stem cells grow into cartilage; Thomas Otis and Bennet Novitch ($1,148,758), who are using new techniques to study communication between nerve and muscle cells in spinal muscular atrophy; and Samantha Butler ($598,367), who is investigating the molecular elements that drive stem cells to become the neurons in charge of our sense of touch.

"These basic biology grants form the foundation of the revolutionary advances we are seeing in stem cell science," said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center. "Every cellular therapy that reaches patients must begin in the laboratory with ideas and experiments that will lead us to revolutionize medicine and ultimately improve human life. That makes these awards invaluable to our research effort."

The awards are part of CIRM's Basic Biology V grant program, which fosters cutting-edge research on significant unresolved issues in human stem cell biology, with a focus on unravelling the key mechanisms that determine how stem cells decide which cells they will become. By learning how such mechanisms work, scientists can develop therapies that drive stem cells to regenerate or replace damaged or diseased tissue.

Lili Yang: Tracking special immune cells

The various cells that make up human blood all arise from hematopoietic stem cells. These include special white blood cells called T cells, the "foot soldiers" of the immune system that attack bacteria, viruses and other disease-causing invaders. Among these T cells is a smaller group, a kind of "special forces" unit known as invariant natural killer T cells, or iNKT cells, which have a remarkable capacity to mount immediate and powerful responses to disease when activated and are believed to be important to the immune system's regulation of infections, allergies, cancer and autoimmune diseases such as Type I diabetes and multiple sclerosis.

The iNKT cells develop in small numbers in the blood generally accounting for less than 1 percent of blood cells but can differ greatly in numbers among individuals. Very little is known about how blood stem cells produce iNKT cells.

Visit link:
Stem cell agency's grants to UCLA help set stage for revolutionary medicine

Contact Information

Available for logged-in reporters only

Newswise Scientists from UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received new awards from the California Institute of Regenerative Medicine (CIRM), the state stem cell research agency, that will forward revolutionary stem cell science in medicine.

Recipients included Dr. Lili Yang, assistant professor of microbiology, immunology and molecular genetics who received $614,400 for her project to develop a novel system for studying how stem cells become rare immune cells; Dr. Denis Evseenko, assistant professor of orthopedic surgery, who received $1,146,468 for his project to identify the elements of the biological niche in which stem cells grow most efficiently into articular cartilage cells; Dr. Thomas Otis, professor and chair of neurobiology and Dr. Ben Novitch, assistant professor of neurobiology, who received $1,148,758 for their project using new light-based optigenetic techniques to study the communication between nerve and muscle cells in spinal muscular atrophy, an inherited degenerative neuromuscular disease in children; and Dr. Samantha Butler, assistant professor of neurobiology, received $598,367 for her project on discovering which molecular elements drive stem cells to become the neurons, or nerve cells, in charge of our sense of touch.

These basic biology grants form the foundation of the revolutionary advances we are seeing in stem cell science, said Dr. Owen Witte, professor and director of the Broad Stem Cell Research Center, and every cellular therapy that reaches patients must begin in the laboratory with ideas and experiments that will lead us to revolutionize medicine and ultimately improve human life. That makes these awards invaluable to our research effort.

The awards were part of CIRMs Basic Biology V grant program, carrying on the initiative to foster cutting-edge research on significant unresolved issues in human stem cell biology. The emphasis of this research is on unravelling the secrets of key mechanisms that determine how stem cells, which can become any cell in the body, differentiate, or decide which cell they become. By learning how these mechanisms work, scientists can then create therapies that drive the stem cells to regenerate or replace damaged or diseased tissue.

Using A New Method to Track Special Immune Cells All the different cells that make up the blood come from hematopoietic or blood stem cells. These include special white blood cells called T cells, which serve as the foot soldiers of the immune system, attacking bacteria, viruses and other invaders that cause diseases.

Among the T cells is a smaller group of cells called invariant natural killer T (iNKT) cells, which have a remarkable capacity to mount immediate and powerful responses to disease when activated, a small special forces unit among the foot soldiers, and are believed to be important to immune system regulation of infections, allergies, cancer and autoimmune diseases such as Type I diabetes and multiple sclerosis.

The iNKT cells develop in small numbers in the blood, usually less than 1 percent of all the blood cells, and can differ greatly in numbers between individuals. Very little is known about how the blood stem cells produce iNKT cells.

Dr. Lili Yangs project will develop a novel model system to genetically program human blood stem cells to become iNKT cells. Dr. Yang and her colleagues will track the differentiation of human blood stem cells into iNKT cells providing a pathway to answer many critical questions about iNKT cell development.

View post:
Stem Cell Agency Helps Set the Stage for Revolutionary Medicine

(CNN) We run too hard, we fall down, we're sick - all of this puts stress on the cells in our bodies. But in what's being called a breakthrough in regenerative medicine, researchers have found a way to make stem cells by purposely putting mature cells under stress.

Two new studies published Wednesday in the journal Nature describe a method of taking mature cells from mice and turning them into embryonic-like stem cells, which can be coaxed into becoming any other kind of cell possible. One method effectively boils down to this: Put the cells in an acidic environment.

"I think the process we've described mimics Mother Nature," said Dr. Charles Vacanti, director of the laboratory for Tissue Engineering and Regenerative Medicine at Brigham & Women's Hospital in Boston and senior author on one of the studies. "It's a natural process that cells normally respond to."

Both studies represent a new step in the thriving science of stem cell research, which seeks to develop therapies to repair bodily damage and cure disease by being able to insert cells that can grow into whatever tissues or organs are needed. If you take an organ that's functioning at 10 percent of normal and bring it up to 25 percent functionality, that could greatly reduce the likelihood of fatality in that particular disease, Vacanti said.

This method by Vacanti and his colleagues "is truly the simplest, cheapest, fastest method ever achieved for reprogramming [cells]," said Jeff Karp, associate professor of medicine at the Brigham & Women's Hospital and principal faculty member at the Harvard Stem Cell Institute. He was not involved in the study.

Before the technique described in Nature, the leading candidates for creating stem cells artificially were those derived from embryos and stem cells from adult cells that require the insertion of DNA to become reprogrammable.

Stem cells are created the natural way every time an egg that is fertilized begins to divide. During the first four to five days of cell division, so-called pluripotent stem cells develop. They have the ability to turn into any cell in the body. Removing stem cells from the embryo destroys it, which is why this type of research is controversial.

Researchers have also developed a method of producing embryonic-like stem cells by taking a skin cell from a patient, for example, and adding a few bits of foreign DNA to reprogram the skin cell to become like an embryo and produce pluripotent cells, too. However, these cells are usually used for research because researchers do not want to give patients cells with extra DNA.

The new method does not involve the destruction of embryos or inserting new genetic material into cells, Vacanti said. It also avoids the problem of rejection: The body may reject stem cells that came from other people, but this method uses an individual's own mature cells.

"It was really surprising to see that such a remarkable transformation could be triggered simply by stimuli from outside of the cell," said Haruko Obokata of the Riken Center for Developmental Biology in Japan in a news conference this week.

Original post:
New breakthrough in stem cell research

Current ratings for: Scientists make pure precursor liver and pancreas cells from stem cells

Public / Patient:

0 (0 votes)

Health Professionals:

5 (1 vote)

A new study published in the journal Cell Stem Cell, describes how scientists have developed a way of producing highly sought populations of a pure tissue-specific cell from human pluripotent stem cells.

Human pluripotent stem cells (hPSCs) are precursor cells than can produce over 200 distinct cell types in the human body. They hold great promise for regenerative medicine and drug screening. The idea is to be able to generate a range of pure tissue types by manipulating these precursor cells.

However, it is proving very challenging to obtain large numbers of pure, untainted, tissue-specific cells from hPSCs. Part of the problem is how to ensure they receive highly specific signals, that do not coax them down paths that lead to a range of other tissue types.

Now, a team led by the Genome Institute of Singapore (GIS) in the Agency for Science, Technology and Research (A*STAR) has developed a new way of coaxing hPSCs to produce highly pure populations of endoderm, a valuable cell type that gives rise to organs like the liver and pancreas, bringing closer the day when stem cells can be used in clinical settings.

One of the study leaders is Dr. Bing Lim, senior group leader and associate director of Cancer Stem Cell Biology at the GIS. He and his colleagues developed a highly systematic and novel screening method.

Read more:
Scientists make pure precursor liver and pancreas cells from stem cells

Continue reading page |1|2 |3

The revolutionary discovery that any cell can be rewound to a pre-embryonic state remarkably easily could usher in new therapies and cloning techniques

A LITTLE stress is all it took to make new life from old. Adult cells have been given the potential to turn into any type of body tissue just by tweaking their environment. This simple change alone promises to revolutionise stem cell medicine.

Yet New Scientist has also learned that this technique may have already been used to make a clone. "The implication is that you can very easily, from a drop of blood and simple techniques, create a perfect identical twin," says Charles Vacanti at Harvard Medical School, co-leader of the team involved.

Details were still emerging as New Scientist went to press, but the principles of the new technique were outlined in mice in work published this week. The implications are huge, and have far-reaching applications in regenerative medicine, cancer treatment and human cloning.

In the first few days after conception, an embryo consists of a bundle of cells that are pluripotent, which means they can develop into all cell types in the body. These embryonic stem cells have great potential for replacing tissue that is damaged or diseased but, as their use involves destroying an embryo, they have sparked much controversy.

To avoid this, in 2006 Shinya Yamanaka at Kyoto University, Japan, and colleagues worked out how to reprogram adult human cells into what they called induced pluripotent stem cells (iPSCs). They did this by introducing four genes that are normally found in pluripotent cells, using a harmless virus.

The breakthrough was hailed as a milestone of regenerative medicine the ability to produce any cell type without destroying a human embryo. It won Yamanaka and his colleague John Gurdon at the University of Cambridge a Nobel prize in 2012. But turning these stem cells into therapies has been slow because there is a risk that the new genes can switch on others that cause cancer.

Now, Vacanti, along with Haruko Obokata at the Riken Center for Developmental Biology in Kobe, Japan, and colleagues have discovered a different way to rewind adult cells without touching the DNA. The method is striking for its simplicity: all you need to do is place the cells in a stressful situation, such as an acidic environment.

The idea that this might work comes from a phenomenon seen in the plant kingdom, whereby drastic environmental stress can change an ordinary cell into an immature one from which a whole new plant can arise. For example, the presence of a specific hormone has been shown to transform a single adult carrot cell into a new plant. Some adult cells in reptiles and birds are also known to have the ability to do this.

Excerpt from:
Stem cell power unleashed after 30 minute dip in acid

29/01/2014 - 15:56:06Back to World Home

A revolutionary new approach to creating stem cells in the laboratory could open up a new era of personalised medicine, it is claimed.

Scientists have shown it is possible to reprogramme cells into an embryonic-like state simply by altering their environment.

It means in principle that cells can have their developmental clock turned back without directly interfering with their genes something never achieved before.

The cells become pluripotent, having the potential ability to transform themselves into virtually any kind of tissue in the body, from brain to bone.

Reprogramming a patients own cells in this way is seen as the Holy Grail of regenerative medicine, raising the prospect of repairing diseased and damaged organs with new healthy tissue that will not be rejected by the immune system.

Current methods of performing the same trick involve genetic manipulation, which carries with it a serious risk of triggering cancer.

But the new method described in the journal Nature requires no genetic tweaking. Scientists simply bathed immature white blood cells from mice in an acidic solution for 25 minutes.

Tests showed that, stressed in this way, some of the cells lost their blood identity and produced gene markers typical of early embryos.

When these cells were transferred to a special growth-promoting culture medium they began to multiply and acquired features typical of embryonic stem cells.

See the original post:
Stem cell breakthrough may herald age of personalised medicine

In experiments that could open a new era in stem cell biology, scientists have found a cheap and easy way to reprogram mature cells from mice back into an embryonic-like state that allowed them to generate many types of tissue.

The research, described as game-changing by experts in the field, suggests human cells could in future be reprogrammed by the same technique, offering a simpler way to replace damaged cells or grow new organs for sick and injured people.

Chris Mason, chair of regenerative medicine bioprocessing at University College London, who was not involved in the work, said its approach was "the most simple, lowest-cost and quickest method" to generate so-called pluripotent cells - able to develop into many different cell types - from mature cells.

"If it works in man, this could be the game changer that ultimately makes a wide range of cell therapies available using the patient's own cells as starting material - the age of personalized medicine would have finally arrived," he said.

The experiments, reported in two papers in the journal Nature on Wednesday, involved scientists from the RIKEN Center for Developmental Biology in Japan and Brigham and Women's Hospital and Harvard Medical School in the United States.

Beginning with mature, adult cells, researchers let them multiply and then subjected them to stress "almost to the point of death", they explained, by exposing them to various events including trauma, low oxygen levels and acidic environments.

Within days, the scientists found that the cells survived and recovered from the stressful stimulus by naturally reverting into a state similar to that of an embryonic stem cell.

These stem cells created by this exposure to stresses - dubbed STAP cells by the researchers - were then able to differentiate and mature into different types of cells and tissue, depending on the environments they were given.

"If we can work out the mechanisms by which differentiation states are maintained and lost, it could open up a wide range of possibilities for new research and applications using living cells," said Haruko Obokata, who lead the work at RIKEN.

Stem cells are the body's master cells and are able to differentiate into all other types of cells. Scientists say that, by helping to regenerate tissue, they could offer ways of tackling diseases for which there are currently only limited treatments - including heart disease, Parkinson's and stroke.

See the rest here:
Scientists create embryonic-type stem cells without embryos

Haruko Obokata / Nature

Japanese researchers have created a new type of stem cell just by pressuring normal cells in the body. This image shows a mouse embryo created using these cells, which are genetically engineered to glow green.

Scientists have made a whole new type of stem cell using little more than a little acid, and they say it may represent a way to skip all the complex and controversial steps that it now takes to make cells to regenerate tissues and organs.

The team in Japan includes some of the foremost experts in making what are called pluripotent stem cells master cells that have the power to morph into any type of cells, from blood to bone to muscle. These master cells look and act like an embryo right after conception and, like a days-old embryo, have the power to generate new tissue of any type.

Making these powerful cells usually requires the use of embryos something many disapprove of or tricky mixtures of genes to turn back the clock.

While theres not an immediate use for the discovery, it could add to the arsenal of tools that scientists can use in trying to find ways to repair the human body, the team reports in this weeks issue of the journal Nature.

It is also exciting to think about the new possibilities this finding offers, not only in areas like regenerative medicine but also perhaps in the study of senescence and cancer as well, Haruko Obokata of the RIKEN Center for Developmental Biology in Kobe, Japan, told reporters in a conference call.

Obokatas team worked with mice, and found they could get ordinary cells from baby mice to turn into pluripotent stem cells by bathing them in a slightly acidic solution. They call them stimulus-triggered acquisition of pluripotency, or STAP, cells.

Other stem cells experts praised the work. These breakthroughs are so impressive and potentially powerful truly another dramatic game-changer, said Dr. Gerald Schatten, a stem cell and genetic engineering expert at the University of Pittsburgh.

If reproducible in humans, this will be a paradigm changer," said Dr. Robert Lanza of Massachusetts-based Advanced Cell Technology, a company developing stem cell-based treatments.

Follow this link:
Scientists make a new type of stem cell, using a little acid

In experiments that could open a new era in stem cell biology, scientists have found a simple way to reprogramme mature animal cells back into an embryonic-like state that allows them to generate many types of tissue.

The research, described as game-changing by experts in the field, suggests human cells could in future be reprogrammed by the same technique, offering a simpler way to replace damaged cells or grow new organs for sick and injured people.

Chris Mason, chair of regenerative medicine bioprocessing at University College London, who was not involved in the work, said its approach in mice was "the most simple, lowest-cost and quickest method" to generate so-called pluripotent cells - able to develop into many different cell types - from mature cells.

"If it works in man, this could be the game changer that ultimately makes a wide range of cell therapies available using the patient's own cells as starting material - the age of personalised medicine would have finally arrived," he said.

The experiments, reported in two papers in the journal Nature on Wednesday, involved scientists from the RIKEN Center for Developmental Biology in Japan and Brigham and Women's Hospital and Harvard Medical School in the United States.

The researchers took skin and blood cells, let them multiply, then subjected them to stress "almost to the point of death", they explained, by exposing them to various events including trauma, low oxygen levels and acidic environments.

One of these "stressful" situations was simply to bathe the cells in a weak acid solution for around 30 minutes.

Within days, the scientists found that the cells had not only survived but had also recovered by naturally reverting into a state similar to that of an embryonic stem cell.

These stem cells - dubbed Stimulus-Triggered Acquisition of Pluripotency, or STAP, cells by the researchers - were then able to differentiate and mature into different types of cells and tissue, depending on the environments they were put in.

"NEW ERA"

Read the original post:
Scientists hail stem cell breakthrough

28 January 2014-Scientists from the Genome Institute of Singapore (GIS) in A*STAR have developed a novel method of directing human pluripotent stem cells (hPSCs) into highly pure populations of endoderm[1], a valuable cell type that gives rise to organs including the liver and pancreas.

These cells are highly sought-after for therapeutic and biotechnological purposes, but have been historically difficult to attain from hPSCs. The ability to generate pure endoderm at higher yields from hPSCs is a key and important step towards the use of stem cells in clinical applications.

The discovery, published in the prestigious scientific journal Cell Stem Cell in January 2014, was led by Dr Bing Lim, Senior Group Leader and Associate Director of Cancer Stem Cell Biology at the GIS, Dr Lay Teng Ang, a postdoctoral fellow from Dr Lims lab, and Kyle Loh, a graduate student at Stanford University School of Medicine.

hPSCs are stem cells that can generate over 200 distinct cell types in the human body. They respond to multiple external protein instructions to differentiate into other cell types. Therefore, generating one single cell type from hPSCs, and a pure population of that given cell type, is delicate as hPSCs have a tendency to also form other types of cells.

Employing a highly systematic and novel approach, the group screened for proteins and chemicals that promote the formation of a single desired cell type, and concurrently block induction of unwanted cell types. This strategy uncovered a combination of triggers that could drive hPSCs towards pure populations of endoderm. The valuable cells produced and the insights gained from this work have brought stem cells one step closer to clinical translation and furthered basic research into the understanding of how cell fates are specified during stem cell differentiation.

View post:
:: 28, Jan 2014 :: SINGAPORE SCIENTISTS SUCCEED IN MANIPULATING STEM CELLS INTO LIVER AND PANCREAS PRECURSOR CELLS

Embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body.

Stem cells can be manufactured for human use for the first time in Ireland, following Irish Medicines Board licensing of a new facility in Galway.

NUI Galways Centre for Cell Manufacturing Ireland aims to culture adult stem cells to tackle conditions such as arthritis, heart disease, diabetes and associated conditions.

The centre, which is one of less than half a dozen in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

Stem cells serve as the bodys repair mechanism. They can be isolated from tissues such as bone marrow and fat, and cultured in laboratory settings.

More controversially, embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body, but scientists can now use reprogrammed adult skin cells to create a stem cell that is very similar to embryonic versions.

The centre will be opened today by Minister of State for Research and Innovation Sen Sherlock, at a time when the Health Research Board and Science Foundation Ireland have approved funding there for clinical trials on using mesenchymal stem cells cells that can differentiate into a variety of types for treatment of critical limb ischemia, a condition associated with diabetes that can result in amputation.

The new centres director Prof Tim OBrien explained that the stem cells must be grown in the laboratory to generate sufficient quantities, following their isolation from the bone marrow of adult donors, and the facility will help Ireland to develop therapies for a broad range of clinical problems which do not have effective treatments today.

It will also allow us to translate discoveries from the basic stem cell research programme led by Prof Frank Barry at the Science Foundation Ireland-funded REMEDI to the clinic, and to be competitive for grant funding under the Horizon 2020 programme of the EU, he said.

Stem cell research in Ireland is in what scientists have described as a legislative lacuna, but this relates to use of embryonic stem cells and does not in any way inhibit the use of adult stem cells, Prof OBrien explained.

Read the original post:
Ireland’s first stem cell manufacturing centre approved at NUI Galway

Embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body.

Stem cells can be manufactured for human use for the first time in Ireland, following Irish Medicines Board licensing of a new facility in Galway.

NUI Galways Centre for Cell Manufacturing Ireland aims to culture adult stem cells to tackle conditions such as arthritis, heart disease, diabetes and associated conditions.

The centre, which is one of less than half a dozen in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

Stem cells serve as the bodys repair mechanism. They can be isolated from tissues such as bone marrow and fat, and cultured in laboratory settings.

More controversially, embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body, but scientists can now use reprogrammed adult skin cells to create a stem cell that is very similar to embryonic versions.

The centre will be opened today by Minister of State for Research and Innovation Sen Sherlock, at a time when the Health Research Board and Science Foundation Ireland have approved funding there for clinical trials on using mesenchymal stem cells cells that can differentiate into a variety of types for treatment of critical limb ischemia, a condition associated with diabetes that can result in amputation.

The centres director, Prof Tim OBrien, saidstem cell research in Ireland is in a legislative lacuna, but this relates to use of embryonic stem cells and does not in any way inhibit the use of adult stem cells.

Original post:
Island’s first stem cell manufacturing centre approved at NUI Galway

Philadelphia, PA (PRWEB) January 23, 2014

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of combinatorial biologics for regeneration and disease reversion in human organs and tissues, today announces the appointment of Dr. Joel I. Osorio MD, as VP of International Clinical Development.

We are honored to have someone with Dr. Osorios experience join us as we execute on a globalized clinical strategy, said Ira S. Pastor, CEO, Bioquark Inc. His broad clinical experience in functional anti-aging regenerative and stem cell based medicine make him a very valuable addition to the Bioquark team.

Dr. Osorio brings over 9 years of experience in medical practice, both in the private practice and public medical settings. Currently the medical director of the medical spa Bamboo Rejuvenecimiento Facial y Coporal (http://www.bamboobelleza.com), Dr. Osorio has served in capacities in both private and public practice, as a hospital staff physician, and as emergency health services coordinator for a variety of private and public institutions throughout Mexico. He earned MD degrees at both Westhill University and the National Autonomous University of Mexico as a medical surgeon, has diplomas in aesthetic medicine from the Autonomous University of Guadalajara, is an Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine (http://www.a4m.com/joel-osorio-bamboo-rejuvenecimiento-facial-y-corporal-naucalpan-estado-de-mxico.html), is a visiting scholar at University of North Carolina at Chapel Hill in dermatology, a fellow in stem cell medicine by the American Academy of Anti-Aging Medicine and University of South Florida, and currently is completing additional masters work in metabolic and nutrition sciences at University of South Florida. Dr. Osorio is also a member of the round table of ReGeNeRaTe Laboratories Mexico Committee (a DNAge-Lab Company), and has been actively working in the applied stem cell field since 2007. In 2011, Dr. Osorio became a member of the International Cellular Medicine Society, is a PRP certified practitioner in aesthetic and regenerative fields, and from 2009 to 2012 managed the blood bank at Ruben Lenero public hospital. Dr. Osorio frequently appears on Mexican national television programs and interviews regularly as a speaker on the topic of anti-aging (http://www.youtube.com/watch?v=Z4SvkBTS-P0) as well as contributes in various magazines and periodicals on anti-aging related subjects.

I am very excited about the candidates being developed at Bioquark and their very novel approach to human regeneration and disease reversion, as well as the broader biological programs focused on anti-aging," said Dr. Osorio. "I'm pleased to be joining the team and am looking forward to playing a more active role in this truly transformational platform."

About Bioquark, Inc. Bioquark Inc. (http://www.bioquark.com) is focused on the development of biologic based products that have the ability to alter the regulatory state of human tissues and organs, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

Excerpt from:
Bioquark Inc. Appoints Dr. Joel I. Osorio MD, Specialist in Functional Anti-Aging Regenerative and Stem Cell Medicine ...

Jan. 22, 2014 Scientists have known for years that stem cells in male and female sexual organs are regulated differently by their respective hormones. In a surprising discovery, researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) and Baylor College of Medicine have found that stem cells in the blood-forming system -- which is similar in both sexes -- also are regulated differently by hormones, with estrogen proving to be an especially prolific promoter of stem cell self-renewal.

The research, published in Nature, raises several intriguing possibilities for further investigation that might lead to improved treatments for blood cancers and increased safety and effectiveness of chemotherapy.

Before the finding, blood-forming stem cells were thought to be regulated similarly in both males and females, according to the paper's senior author, Dr. Sean Morrison, Director of CRI, Professor of Pediatrics, and the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern Medical Center.

However, while working in Dr. Morrison's laboratory as postdoctoral fellows, Dr. Daisuke Nakada, the first and co-corresponding author of the study, and Dr. Hideyuki Oguro discovered that blood-forming stem cells divide more frequently in females than in males due to higher estrogen levels. The research, conducted using mice, demonstrated that the activity of blood-forming stem cells was regulated by systemic hormonal signals in addition to being regulated by local changes within the blood-forming system.

"This discovery explains how red blood cell production is augmented during pregnancy," said Dr. Morrison. "In female mice, estrogen increases the proliferation of blood-forming stem cells in preparation for pregnancy. Elevated estrogen levels that are sustained during pregnancy induce stem cell mobilization and red cell production in the spleen, which serves as a reserve site for additional red blood cell production."

The study involved treating male and female mice over a period of several days with amounts of estrogen needed to achieve a level consistent with pregnancy. When an estrogen receptor that is present within blood-forming stem cells was deleted from those cells, they were no longer able to respond to estrogen, nor were they able to increase red blood cell production. The results demonstrate that estrogen acts directly on the stem cells to increase their proliferation and the number of red blood cells they generate.

"If estrogen has the same effect on stem cells in humans as in mice, then this effect raises a number of possibilities that could change the way we treat people with diseases of blood cell-formation," said Dr. Morrison. "Can we promote regeneration in the blood-forming system by administering estrogen? Can we reduce the toxicity of chemotherapy to the blood-forming system by taking into account estrogen levels in female patients? Does estrogen promote the growth of some blood cancers? There are numerous clinical opportunities to pursue."

View original post here:
Scientists find estrogen promotes blood-forming stem cell function

TAMPA, Fla. (PRWEB) January 22, 2014

Societys continual, obsessive search for perpetual youth has lead many on a tumultuous path of medical mayhem from shots to creams and a variety of procedures in between.

A leader in modern medicine, Dr. Burton Feinerman has always been at the forefront of new and life changing procedures in the healthcare community. Feinerman's experience includes his time as a key research associate at the Papanicolau Cancer Research Institute in Miami.

His career took a glamorous turn when he became a concierge physician to the stars at his office in Maui, Hawaii. He has treated a variety of high-profile clientele including celebrities Eddie Murphy, Larry David, Pink, Brittney Spears, Nick Nolte, Christian Slater, Arnold Schwarzenegger and Oprah, who once thanked him with an autographed magazine for the shot in the tush.

Staying true to his mission to find relief for those afflicted with incurable diseases, Feinerman soon focused his efforts on the innovative and unfamiliar world of cell regeneration and gene therapy. As one of the original physician scientists to create stem cell protocols for incurable diseases, Feinerman now runs his clinic in Tampa, Fla. where he treats patients with conditions such as Alzheimers, ALS, Autism, brain damage, Cerebral Palsy, Multiple Sclerosis, Spinal Cord Injury, Parkinsonism, Heart Disease, COPD, diabetes, Chronic Kidney Disease, Pulmonary Fibrosis, Tay Sachs, Sandhoff Disease, Stargardt Disease, Huntington Disease, Scleroderma, Lupus, Rheumatoid Arthritis, Crohns Disease, cancer of all types, Macular Degeneration and Retinitis Pigmentosa.

The emerging developments in stem cell therapy, gene therapy, nanotechnology and tissue engineering offer new hope to millions of patients, said Feinerman.

Stem Cells and Sex Wars By: Dr. Burton Feinerman ISBN: 978-1481774789 Available at Amazon, Barnes and Noble and Authorhouse online bookstores.

About the authors A graduate of New York Medical College, Dr. Burton Feinerman also received extensive postgraduate training from Long Island College Hospital and the Mayo Clinic. He served as chief medicine for the U.S. Army, as part of the 98th General Hospital in Germany as well as chairman of medicine at Miami General Hospital, Opa-Locka Hospital, N. Miami General Hospital and chairman of cancer technologies Kids Medical Centers of America. Active in many industry organizations, Feinerman is a member of the Society of Apheresis, the Society of Bone Marrow Blood Transplantation, the International Society for Cellular Therapy, the Society for Cranial Transplantation and Brain Repair, and the Society for Cardiac Translational Therapy. With over 55 years of experience in medical practice, he is currently the president and CEO of Stem Cell Regen Med.

See the rest here:
Dr. Burton Feinerman Shares Experiences from Celebrity Care to Modern Medicine

By Gu Yang

According to statistics, up to August 1st, 2013, clinical trials on stem cell research publicly registered on the website of Clinical Trial have reached 4704, among which 213 were from China. Though it is far from 2805 of the US, Xu Xiaochun, the director of INCOSC and founder of Boya Life, insists that gap between China and developed countries in stem cell research field is not big -- "we are almost starting at the same time, since the key technology of stem cell has just got breakthrough in recent two or three years, and the development history of the whole industry is just 20 years."

"This is an original contribution in science which is most likely to be accomplished by China!" Xu Xiaochun stated briefly. The next few years will be the critical period for the development of global stem cell industry, and China is not to miss this valuable but fleeting opportunity.

A "gold mine" of USD400 billion is to be discovered

Who will be the next Microsoft? Even Gates himself admits that this company will surely come from the field of biological medicine, and it has been a consensus in the industry that stem cell industry is one of the cores and the most promising modules in the field of biological medicine.

In global market, stem cell technology and its development has been crazily pursued by international capital market in recent years, and relevant market value of stem cell concept stocks listed in NASDAQ only has exceeded USD30 billion. It is predicted by experts that the potential market of global stem cell industry will be about USD80 billion within the next two years, and reach up to USD400 billion around 2020.

In China, the stem cell industry also has bright prospects. According to the research reports from the institution named First Capital, the stem cell industry of China has formed a complete industry chain from the upstream storage to the downstream clinical application, and it is predicted that the income of stem cell industry in the coming 5 years will increase to RMB 30 billion from the current RMB 2 billion, at the average annual growth rate of 170 percent.

For many people, the stem cell, with the ability to repair and generate all human cells, has not been a strange concept. However, there are still some widespread misunderstandings in society about the cognition of stem cells in clinical application.

"Stem cell application doesn't only mean the storage of stem cells, but it has many downstream applications. Moreover, stem cells can also be used as a tool for new medicine research and development as well as other personalized medicine." Xu Xiaochun told the journalist that, Boya Life, founded by him, is such a group starting from stem cell research, turns the view to the whole field of biological economy while constantly extending upstream and downstream on the industry chain.

Read the original:
Stem cell industry ready to liftoff

PUBLIC RELEASE DATE:

14-Jan-2014

Contact: Michelle Quivey mquivey@isscr.org 224-592-5012 International Society for Stem Cell Research

CHICAGO The International Society for Stem Cell Research (ISSCR) has announced the following 2014 award recipients, who will be formally recognized at its 12th Annual Meeting in Vancouver, taking place June 18-21, 2014:

The McEwen Award for Innovation, supported by the McEwen Centre for Regenerative Medicine, recognizes original thinking and groundbreaking research pertaining to stem cells or regenerative medicine that opens new avenues of exploration toward the understanding or treatment of human disease or affliction. The winner receives $100,000 USD. Past winners include James Thomson, Rudolf Jaenisch, Kazutoshi Takahashi and Shinya Yamanaka.

Award recipient Surani is a world leader in the field of epigenetics and the development of the mammalian germ line. His work on early mammalian development led to his involvement in the discovery of genomic imprinting and ongoing contributions to understanding the mechanistic basis of imprinting. Most relevant to stem cell biology, is his work on the cellular and molecular specification of the mammalian germ cell lineage, which impacted the field's understanding of how the germ line is established and the molecular mechanisms responsible for reprogramming the epigenome in order to generate the totipotent state.

"The ISSCR is thrilled to announce the McEwen Award for Innovation, our most prestigious award, will be presented to Azim Surani," Janet Rossant, ISSCR president, said. "His pioneering research, which has changed the face of epigenetics and advanced the field of stem cell biology, is a rare and significant contribution from a single individual."

The ISSCR-BD Biosciences Outstanding Young Investigator Award recognizes exceptional achievements by an ISSCR member and investigator in the early part of their independent career in stem cell research. The winner receives a $7,500 USD personal award and an opportunity to present at the ISSCR Annual Meeting. Past winners include Marius Wernig, Cdric Blanpain, Robert Blelloch, Joanna Wysocka and Konrad Hochedlinger.

Award recipient Greco established a noninvasive method to directly visualize skin stem cell division in real time in living animals the first of its kind for imaging any stem cell. By combining this method with laser ablation and transgenic lineage tracing, she captured previously inaccessible key information on stem cell behavior during tissue maintenance and regeneration. She demonstrated that the niche location of stem cells dictates their fates, the niche is required for tissue maintenance, and that a -catenin-mediated extrinsic mechanism regulates stem cell activation.

"The ISSCR is looking forward to presenting our Outstanding Young Investigator Award to Valentina Greco," Rossant said. "Her enthusiastic nomination by over a dozen leaders in the field of stem cell research demonstrates the significance of her early-career contributions to stem cell biology and regenerative medicine."

Follow this link:
The International Society for Stem Cell Research announces its 2014 award recipients

ST. LOUIS -

Sickle cell is a serious disease that causes pain, anemia, infection, organ damage and even stroke. Its the most common inherited blood disorder in the United States.

The good news is bone marrow transplants can be a cure. The bad news is not every patient has a matching donor. Now, researchers are looking at a new way to offer more patients transplants.

Madisyn Travis is like any other 9-year-old, but theres something that sets Madisyn apart. She has sickle cell, an inherited red blood cell disease.

"It makes me feel bad, and sometimes I have to go to the hospital," Madisyn said.

"It's really hard to see her life interrupted," said Denise Travis, Madisyn's mom.

Soon, however, Madisyn will get a bone marrow transplant to cure her disease. Her little brother or sister are both matches, and one will be the donor.

Madisyn is one of the lucky ones. Only 14 percent of patients have a matching sibling.

"Ten years ago, we'd just tell them, 'Sorry, you have no family member. We cant transplant you,'" said Dr. Shalini Shenoy, professor of pediatrics and medical director, pediatric stem cell transplant program, Washington University School of Medicine, St. Louis Children's Hospital.

Shenoy is studying a new option for patients without related donors. Stem cells from a baby's umbilical cord can be infused in the arm. They travel to the bone marrow, settle there and make new cells.

See the article here:
Health Beat: Stem cells to cure sickle cell